ArticleBlood2013
TMA: beware of complements.
Article in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.Bone marrow transplantation · 2018Trial
- Complement-related genetic analysis for Japanese children with transplant-associated thrombotic microangiopathy.Frontiers in pediatrics · 2026Article
- Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study.Bone marrow transplantation · 2022Article
- Pre-transplant use of tyrosine kinase inhibitors and transplant associated thrombotic microangiopathy - a single centre analysis of incidence, risk factors and outcomes.Bone marrow transplantation · 2021Article
- A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant.Blood advances · 2021Article
- Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.Blood advances · 2019Review
- Thrombotic microangiopathy following haematopoietic stem cell transplant.Pediatric nephrology (Berlin, Germany) · 2018Review
- Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.Bone marrow transplantation · 2018Review
- The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy.Blood · 2016Article
- Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Article
- Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2014Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of Blood, Jodele and colleagues report that defective complement regulation contributes to the development of thrombotic microangiopathy (TMA) after hematopoietic stem cell transplantation (HSCT) with important implications for diagnosis and management of this severe clinical complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.